CVS Health Corporation $CVS Holdings Trimmed by Ameriflex Group Inc.

Key Points

• Ameriflex Group Inc. reduced its stake in CVS Health by 86% during Q2, now holding just 569 shares valued at approximately $39,000.
• Analysts have upgraded CVS Health's stock ratings, with Barclays raising its price target from $80 to $87 and UBS upgrading it from "neutral" to "buy" while increasing the target from $67 to $79.
• CVS Health announced a quarterly dividend of $0.665 per share, representing a yield of 3.4%, with the payment date set for November 3rd.

Ameriflex Group Inc. reduced its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 86.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 569 shares of the pharmacy operator's stock after selling 3,502 shares during the period. Ameriflex Group Inc.'s holdings in CVS Health were worth $39,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of CVS. Vest Financial LLC lifted its stake in CVS Health by 73.5% during the first quarter. Vest Financial LLC now owns 16,707 shares of the pharmacy operator's stock valued at $1,132,000 after purchasing an additional 7,077 shares during the last quarter. SeaCrest Wealth Management LLC increased its holdings in shares of CVS Health by 4.4% in the first quarter. SeaCrest Wealth Management LLC now owns 8,136 shares of the pharmacy operator's stock valued at $551,000 after buying an additional 344 shares in the last quarter. Pines Wealth Management LLC bought a new stake in shares of CVS Health during the 1st quarter worth $340,000. Sivia Capital Partners LLC acquired a new position in shares of CVS Health in the 1st quarter worth $241,000. Finally, Eagle Wealth Strategies LLC acquired a new stake in shares of CVS Health during the first quarter worth $241,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.22% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on CVS shares. Barclays increased their price target on CVS Health from $80.00 to $87.00 and gave the company an "overweight" rating in a research report on Thursday, September 4th. Sanford C. Bernstein lifted their target price on shares of CVS Health from $72.00 to $77.00 and gave the stock a "market perform" rating in a research report on Friday, September 5th. Wall Street Zen upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Sunday, September 21st. Wolfe Research lifted their price objective on shares of CVS Health from $80.00 to $85.00 and gave the stock an "outperform" rating in a research report on Monday, September 22nd. Finally, UBS Group upgraded CVS Health from a "neutral" rating to a "buy" rating and increased their target price for the company from $67.00 to $79.00 in a report on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $78.25.

CVS Health Stock Up 0.1%

CVS stock opened at $77.51 on Monday. The company has a 50 day moving average of $70.71 and a two-hundred day moving average of $67.32. The company has a market cap of $98.31 billion, a price-to-earnings ratio of 21.65, a PEG ratio of 0.85 and a beta of 0.60. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $79.20. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. CVS Health's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is currently 74.30%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.